Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Stock Information for Citius Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Oncology Inc.

Exagen Inc. Prices Public Offering of Common Stock
Exagen Inc. Announces Proposed Public Offering of Common Stock
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
Exagen Inc. to Participate in Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.